Modified soluble FGF receptor FC fusions with improved biological activity
IL178025D0
Method for purifying plasmid dna
WO2006128740A2
Anti-vascular methods and therapies employing lysyl oxidase inhibitors
ZA200602244B
Method of preparation of pharmaceutically grade plasmid DNA
ZA200509830B
Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
NZ553914A
Stable liquid formulations of plasmid DNA at low buffer concentration
ZA200702211B
Stable liquid formulations of plasmid DNA
EP2246413A2
Method for purifying plasmid DNA having pharmaceutical quality
EP1687642A2
Screening methods for combinations of biological compounds
CA2536931A1
Method of preparation of pharmaceutically grade plasmid dna
NZ543717A
Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes
US7364894B2
Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
IL152860A
Purification of dna by a triple helix formation with an immobilized oligonucleotide
US7279313B2
Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7038026B2
Purification of a triple heli formation with an immobilized oligonucleotide
